The complicated skin and skin structure infections drugs market size has grown strongly in recent years. It will grow from $10.36 billion in 2025 to $11.31 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to high incidence of bacterial skin infections, growing awareness of healthcare-associated infections, increased hospital admissions due to csssi, adoption of intravenous antibiotic therapy, availability of generic antibiotics.
The complicated skin and skin structure infections drugs market size is expected to see rapid growth in the next few years. It will grow to $16.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to emergence of multidrug-resistant bacteria, advancements in targeted antibiotic therapies, integration of digital health for infection management, rising demand for outpatient treatment options, expansion of biologics and novel antimicrobial agents. Major trends in the forecast period include rising prevalence of antibiotic-resistant skin infections, development of novel antibiotics for deep tissue infections, adoption of advanced drug delivery systems, increasing hospitalization and outpatient care for csssi, focus on patient-centric therapeutic regimens.
The increasing prevalence of skin disease is expected to drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market going forward. Skin diseases are medical conditions that affect the appearance, structure, and function of the skin, and can also involve hair, nails, and related tissues. Various antibiotic drugs are used to treat resistant bacteria in cSSSI. As a result, the rise in skin disease cases can lead to new cSSSI drug approvals, increase awareness, and encourage early diagnosis of complicated skin and skin structure infections. For instance, in February 2023, according to Cancer Research UK, a UK-based cancer research organization, the average number of new melanoma cases each year in the UK is expected to rise from approximately 20,800 cases in 2023-2025 to around 26,500 cases in 2038-2040. This represents a projected 9% increase in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Therefore, the increasing prevalence of skin disease is driving the growth of the complicated skin and skin structure infections drugs market.
Major companies operating in the complicated skin and skin structure infections drugs market are focusing on developing innovative products, such as dalbavancin, to gain a competitive edge. Dalbavancin is a second-generation semi-synthetic lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis, effectively killing gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), making it useful in treating acute bacterial skin and skin structure infections (ABSSSI). For instance, in January 2023, AbbVie Inc., a US-based pharmaceutical company, announced the expansion of Xydalba (dalbavancin for injection) approval for pediatric patients across Europe. Xydalba is an intravenous therapy indicated for acute bacterial skin and skin structure infections in adults and children from three months of age. Its features include a long half-life that allows infrequent dosing, potent activity against resistant gram-positive pathogens, and a favorable safety profile, supporting clinicians in managing complicated infections efficiently.
In September 2023, Novo Holdings, a Denmark-based investment firm, acquired Paratek Pharmaceuticals Inc. for $462 million. Through this acquisition, Novo Holdings aimed to advance its antimicrobial-resistance (AMR) strategy and secure in-market assets targeting acute bacterial skin and skin structure infections (ABSSSI), thereby strengthening its presence in the high-priority anti-infective drugs sector. Paratek Pharmaceuticals is a US-based pharmaceutical company specializing in drugs such as NUZYRA (omadacycline), approved for the treatment of acute bacterial skin and skin structure infections in adults.
Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 202. The regions covered in the complicated skin and skin structure infections drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the complicated skin and skin structure infections drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the complicated skin and skin structure infections drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized manufacturing equipment. This has affected the production and pricing of key antibiotics and parenteral formulations, particularly in regions such as North America and Europe that rely on imports from Asia. Hospital and specialty clinic segments are most impacted due to dependency on high-cost injectable therapies. However, tariffs have encouraged local manufacturing and development of cost-optimized formulations, potentially enhancing domestic supply chains and fostering innovation.
The complicated skin and skin structure infections drugs market research report is one of a series of new reports that provides complicated skin and skin structure infections drugs market statistics, including complicated skin and skin structure infections drugs industry global market size, regional shares, competitors with a complicated skin and skin structure infections drugs market share, detailed complicated skin and skin structure infections drugs market segments, market trends and opportunities, and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. This complicated skin and skin structure infections drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drugs for complicated skin and skin structure infections (cSSSI) are medications used to treat various skin and soft tissue infections (SSTIs) that affect the skin and deeper soft tissues, including muscles, fascia, and subcutaneous tissues, caused by bacterial species. Effective management of these infections is essential to prevent complications and improve patient outcomes.
The main types of active ingredients in drugs for complicated skin and skin structure infections include delafloxacin, vancomycin, ceftaroline fosamil, linezolid, and others. Delafloxacin is a fluoroquinolone antibiotic used to treat skin and skin structure infections caused by specific bacteria. These drugs can be administered orally, topically, or parenterally and are used by end users such as hospitals, home care providers, specialty clinics, and others.
The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The complicated skin and skin structure infections drugs market size is expected to see rapid growth in the next few years. It will grow to $16.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to emergence of multidrug-resistant bacteria, advancements in targeted antibiotic therapies, integration of digital health for infection management, rising demand for outpatient treatment options, expansion of biologics and novel antimicrobial agents. Major trends in the forecast period include rising prevalence of antibiotic-resistant skin infections, development of novel antibiotics for deep tissue infections, adoption of advanced drug delivery systems, increasing hospitalization and outpatient care for csssi, focus on patient-centric therapeutic regimens.
The increasing prevalence of skin disease is expected to drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market going forward. Skin diseases are medical conditions that affect the appearance, structure, and function of the skin, and can also involve hair, nails, and related tissues. Various antibiotic drugs are used to treat resistant bacteria in cSSSI. As a result, the rise in skin disease cases can lead to new cSSSI drug approvals, increase awareness, and encourage early diagnosis of complicated skin and skin structure infections. For instance, in February 2023, according to Cancer Research UK, a UK-based cancer research organization, the average number of new melanoma cases each year in the UK is expected to rise from approximately 20,800 cases in 2023-2025 to around 26,500 cases in 2038-2040. This represents a projected 9% increase in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Therefore, the increasing prevalence of skin disease is driving the growth of the complicated skin and skin structure infections drugs market.
Major companies operating in the complicated skin and skin structure infections drugs market are focusing on developing innovative products, such as dalbavancin, to gain a competitive edge. Dalbavancin is a second-generation semi-synthetic lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis, effectively killing gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), making it useful in treating acute bacterial skin and skin structure infections (ABSSSI). For instance, in January 2023, AbbVie Inc., a US-based pharmaceutical company, announced the expansion of Xydalba (dalbavancin for injection) approval for pediatric patients across Europe. Xydalba is an intravenous therapy indicated for acute bacterial skin and skin structure infections in adults and children from three months of age. Its features include a long half-life that allows infrequent dosing, potent activity against resistant gram-positive pathogens, and a favorable safety profile, supporting clinicians in managing complicated infections efficiently.
In September 2023, Novo Holdings, a Denmark-based investment firm, acquired Paratek Pharmaceuticals Inc. for $462 million. Through this acquisition, Novo Holdings aimed to advance its antimicrobial-resistance (AMR) strategy and secure in-market assets targeting acute bacterial skin and skin structure infections (ABSSSI), thereby strengthening its presence in the high-priority anti-infective drugs sector. Paratek Pharmaceuticals is a US-based pharmaceutical company specializing in drugs such as NUZYRA (omadacycline), approved for the treatment of acute bacterial skin and skin structure infections in adults.
Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 202. The regions covered in the complicated skin and skin structure infections drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the complicated skin and skin structure infections drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the complicated skin and skin structure infections drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized manufacturing equipment. This has affected the production and pricing of key antibiotics and parenteral formulations, particularly in regions such as North America and Europe that rely on imports from Asia. Hospital and specialty clinic segments are most impacted due to dependency on high-cost injectable therapies. However, tariffs have encouraged local manufacturing and development of cost-optimized formulations, potentially enhancing domestic supply chains and fostering innovation.
The complicated skin and skin structure infections drugs market research report is one of a series of new reports that provides complicated skin and skin structure infections drugs market statistics, including complicated skin and skin structure infections drugs industry global market size, regional shares, competitors with a complicated skin and skin structure infections drugs market share, detailed complicated skin and skin structure infections drugs market segments, market trends and opportunities, and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. This complicated skin and skin structure infections drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drugs for complicated skin and skin structure infections (cSSSI) are medications used to treat various skin and soft tissue infections (SSTIs) that affect the skin and deeper soft tissues, including muscles, fascia, and subcutaneous tissues, caused by bacterial species. Effective management of these infections is essential to prevent complications and improve patient outcomes.
The main types of active ingredients in drugs for complicated skin and skin structure infections include delafloxacin, vancomycin, ceftaroline fosamil, linezolid, and others. Delafloxacin is a fluoroquinolone antibiotic used to treat skin and skin structure infections caused by specific bacteria. These drugs can be administered orally, topically, or parenterally and are used by end users such as hospitals, home care providers, specialty clinics, and others.
The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Complicated Skin and Skin Structure Infections Drugs Market Characteristics
3. Complicated Skin and Skin Structure Infections Drugs Market Supply Chain Analysis
4. Global Complicated Skin and Skin Structure Infections Drugs Market Trends and Strategies
5. Complicated Skin and Skin Structure Infections Drugs Market Analysis of End Use Industries
7. Global Complicated Skin and Skin Structure Infections Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Complicated Skin and Skin Structure Infections Drugs Total Addressable Market (TAM) Analysis for the Market
9. Complicated Skin and Skin Structure Infections Drugs Market Segmentation
10. Complicated Skin and Skin Structure Infections Drugs Market Regional and Country Analysis
11. Asia-Pacific Complicated Skin and Skin Structure Infections Drugs Market
12. China Complicated Skin and Skin Structure Infections Drugs Market
13. India Complicated Skin and Skin Structure Infections Drugs Market
14. Japan Complicated Skin and Skin Structure Infections Drugs Market
15. Australia Complicated Skin and Skin Structure Infections Drugs Market
16. Indonesia Complicated Skin and Skin Structure Infections Drugs Market
17. South Korea Complicated Skin and Skin Structure Infections Drugs Market
18. Taiwan Complicated Skin and Skin Structure Infections Drugs Market
19. South East Asia Complicated Skin and Skin Structure Infections Drugs Market
20. Western Europe Complicated Skin and Skin Structure Infections Drugs Market
21. UK Complicated Skin and Skin Structure Infections Drugs Market
22. Germany Complicated Skin and Skin Structure Infections Drugs Market
23. France Complicated Skin and Skin Structure Infections Drugs Market
24. Italy Complicated Skin and Skin Structure Infections Drugs Market
25. Spain Complicated Skin and Skin Structure Infections Drugs Market
26. Eastern Europe Complicated Skin and Skin Structure Infections Drugs Market
27. Russia Complicated Skin and Skin Structure Infections Drugs Market
28. North America Complicated Skin and Skin Structure Infections Drugs Market
29. USA Complicated Skin and Skin Structure Infections Drugs Market
30. Canada Complicated Skin and Skin Structure Infections Drugs Market
31. South America Complicated Skin and Skin Structure Infections Drugs Market
32. Brazil Complicated Skin and Skin Structure Infections Drugs Market
33. Middle East Complicated Skin and Skin Structure Infections Drugs Market
34. Africa Complicated Skin and Skin Structure Infections Drugs Market
36. Complicated Skin and Skin Structure Infections Drugs Market Competitive Landscape and Company Profiles
37. Complicated Skin and Skin Structure Infections Drugs Market Other Major and Innovative Companies
40. Complicated Skin and Skin Structure Infections Drugs Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Complicated Skin And Skin Structure Infections Drugs Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses complicated skin and skin structure infections drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for complicated skin and skin structure infections drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The complicated skin and skin structure infections drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Active Ingredients: Delafloxacin; Vancomycin; Ceftaroline Fosamil; Linezolid; Other Active Ingredients2) By Route of Administration: Oral; Topical; Parenteral
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Delafloxacin: Delafloxacin Oral Tablets; Delafloxacin Injectable Form2) By Vancomycin: Vancomycin Oral Solution; Vancomycin Injection
3) By Ceftaroline Fosamil: Ceftaroline Fosamil Injection
4) By Linezolid: Linezolid Oral Tablets; Linezolid Injectable Form
5) By Other Active Ingredients: Daptomycin; Tigecycline; Teicoplanin
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; GlaxoSmithKline plc; Cipla Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd; Fresenius Kabi; Macleods Pharmaceuticals; Sun Pharmaceutical Industries Limited; Dr Reddy's Laboratories Ltd; Lupin Pharmaceuticals; Zydus Lifesciences Ltd.; Glenmark Pharmaceuticals Ltd.; Alkem Laboratories Limited; Wockhardt; Paratek Pharmaceuticals; Basilea Pharmaceutica AG; Melinta Therapeutics Inc.; Nabriva Therapeutics AG; MerLion Pharmaceuticals GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Complicated Skin and Skin Structure Infections Drugs market report include:- Pfizer Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Cipla Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Fresenius Kabi
- Macleods Pharmaceuticals
- Sun Pharmaceutical Industries Limited
- Dr Reddy's Laboratories Ltd
- Lupin Pharmaceuticals
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Ltd.
- Alkem Laboratories Limited
- Wockhardt
- Paratek Pharmaceuticals
- Basilea Pharmaceutica AG
- Melinta Therapeutics Inc.
- Nabriva Therapeutics AG
- MerLion Pharmaceuticals GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.31 Billion |
| Forecasted Market Value ( USD | $ 16.61 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
